California-based obesity-focused clinical-stage pharma Aardvark Therapeutics saw its shares tumble nearly 26% to $4.99, after it announced that the US Food and Drug Administration (FDA) has placed a ...
Swedish neuroscience specialist BioArctic (Nasdaq Stockholm: BIOA B) said partner Eisai expects Alzheimer’s disease therapy ...
Fasenra (benralizumab) has received US Food and Drug Administration (FDA) approval for the treatment of patients 12 years and older with hypereosinophilic syndrome (HES) without an identifiable ...
US biotech Regenxbio (Nasdaq: RGNX) announced top-line and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY DUCHENNE trial of RGX-202, a potential ...
Vetter is celebrating the start of construction on its new site in Saarlouis with a traditional ground-breaking ceremony today.
Bristol Myers Squibb’s Eliquis (apixaban) is on course for one of the largest single-asset revenue collapses in ...
US regulator the Food and Drug Administration has granted accelerated approval to Beqalzi (sonrotoclax), giving BeOne ...
US biotech major Biogen (Nasdaq: BIIB) today announced top-line results from the Phase II CELIA study evaluating diranersen (BIIB080), an investigational antisense oligonucleotide (ASO) therapy ...
The US Food and Drug Administration (FDA) yesterday approved Inqovi, an oral combination of decitabine and cedazuridine tablets from Taiho Oncology, with venetoclax for the treatment of newly ...
Italian drugmaker Recordati reported first-quarter 2026 revenue of 713 million euros ($775 million) on Tuesday, up 5% year-on ...
US biotech Rigel Pharmaceuticals is betting heavily on the newly-approved breast cancer therapy Veppanu (vepdegestrant), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results